KR20250008764A - 안구 질환의 치료를 위한 보체 인자 i 투여 요법 - Google Patents
안구 질환의 치료를 위한 보체 인자 i 투여 요법 Download PDFInfo
- Publication number
- KR20250008764A KR20250008764A KR1020247040205A KR20247040205A KR20250008764A KR 20250008764 A KR20250008764 A KR 20250008764A KR 1020247040205 A KR1020247040205 A KR 1020247040205A KR 20247040205 A KR20247040205 A KR 20247040205A KR 20250008764 A KR20250008764 A KR 20250008764A
- Authority
- KR
- South Korea
- Prior art keywords
- cfi
- per eye
- weeks
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338392P | 2022-05-04 | 2022-05-04 | |
| US63/338,392 | 2022-05-04 | ||
| PCT/US2023/066620 WO2023215840A1 (en) | 2022-05-04 | 2023-05-04 | Complement factor i dosing regimens for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250008764A true KR20250008764A (ko) | 2025-01-15 |
Family
ID=86760162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247040205A Pending KR20250008764A (ko) | 2022-05-04 | 2023-05-04 | 안구 질환의 치료를 위한 보체 인자 i 투여 요법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250177482A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4518881A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515091A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250008764A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119698286A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265150A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251504A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316772A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400627A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215840A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117551A1 (en) * | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| WO2021257480A2 (en) * | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
-
2023
- 2023-05-04 EP EP23730321.9A patent/EP4518881A1/en active Pending
- 2023-05-04 AU AU2023265150A patent/AU2023265150A1/en active Pending
- 2023-05-04 JP JP2024564919A patent/JP2025515091A/ja active Pending
- 2023-05-04 CA CA3251504A patent/CA3251504A1/en active Pending
- 2023-05-04 IL IL316772A patent/IL316772A/en unknown
- 2023-05-04 KR KR1020247040205A patent/KR20250008764A/ko active Pending
- 2023-05-04 CN CN202380045885.4A patent/CN119698286A/zh active Pending
- 2023-05-04 TW TW112116648A patent/TW202400627A/zh unknown
- 2023-05-04 WO PCT/US2023/066620 patent/WO2023215840A1/en not_active Ceased
-
2024
- 2024-11-01 US US18/935,289 patent/US20250177482A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025515091A (ja) | 2025-05-13 |
| AU2023265150A1 (en) | 2024-11-14 |
| CA3251504A1 (en) | 2023-11-09 |
| CN119698286A (zh) | 2025-03-25 |
| WO2023215840A1 (en) | 2023-11-09 |
| EP4518881A1 (en) | 2025-03-12 |
| IL316772A (en) | 2025-01-01 |
| US20250177482A1 (en) | 2025-06-05 |
| TW202400627A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duh et al. | Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth | |
| KR101682240B1 (ko) | Ace2 폴리펩티드 | |
| KR101993714B1 (ko) | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 | |
| CN100528235C (zh) | 红细胞生成素共轭物 | |
| US12116606B2 (en) | Complement factor I-related compositions and methods | |
| JP2002543837A (ja) | 組換えセトマンナン結合性レクチン | |
| CN103797115A (zh) | 具有快速加工性能的经过修饰的酸性α葡糖苷酶 | |
| CN112384236A (zh) | 用于治疗微血管血栓形成的靶向溶栓 | |
| US5359033A (en) | Cleaved dimers of mullerian inhibiting substance-like polypeptides | |
| JP2022548367A (ja) | 眼科障害の処置または防止における使用のための薬剤 | |
| JPS63102699A (ja) | 新規なdafの製造のための核酸 | |
| CN118804759A (zh) | 补体因子i相关的组合物和方法 | |
| US9469679B2 (en) | Neurturin molecules | |
| US20250177482A1 (en) | Complement factor i dosing regimens for treating ocular diseases | |
| CN116675777A (zh) | 包含补体抑制结构域的多特异性配体结合分子及其用途 | |
| JP2024543158A (ja) | 多重特異性リガンド結合分子及びその用途 | |
| CN101155916A (zh) | 作为血栓溶解剂的靶向性纤溶酶原激活物融合蛋白 | |
| US20040192589A1 (en) | Production of high molecular mass lectins | |
| EP2774935B1 (en) | Improved neurturin molecules | |
| CN116162148A (zh) | 多特异性配体结合分子及其应用 | |
| US20220168434A1 (en) | Application of transthyretin in entering eye and preparing drop | |
| CA3147828C (en) | Agent for use in treatment or prevention of ophthalmic disorders | |
| US6329500B1 (en) | Transforming growth factor-β binding site | |
| CN116635528A (zh) | 补体因子i相关组合物和方法 | |
| KR19980702956A (ko) | 트롬보포이에틴(tpo)의 흡착방지방법 및 안정한 tpo 함유조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |